CD274 and non-small cell lung carcinoma: Phase III studies have now demonstrated improved progression-free (PFS) and overall survival (OS) with PD-L1 inhibitors compared to second-line standard cytotoxic chemotherapy in both squamous and non-squamous NSCLC [2, 3].